Resistance to the mTOR-inhibitor RAD001 elevates integrin α2- and β1-triggered motility, migration and invasion of prostate cancer cells

BACKGROUND: Inhibitors of the mammalian target of rapamycin (mTOR) might become a novel tool to treat advanced prostate cancer. However, chronic drug exposure may trigger resistance, limiting the utility of mTOR inhibitors. METHODS: Metastatic potential of PC3 prostate cancer cells, susceptible (PC3...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsaur, I, Makarević, J, Juengel, E, Gasser, M, Waaga-Gasser, A-M, Kurosch, M, Reiter, M, Wedel, S, Bartsch, G, Haferkamp, A, Wiesner, C, Blaheta, R A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425972/
https://www.ncbi.nlm.nih.gov/pubmed/22782340
http://dx.doi.org/10.1038/bjc.2012.313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425972/
https://www.ncbi.nlm.nih.gov/pubmed/22782340
http://dx.doi.org/10.1038/bjc.2012.313

Ejemplares similares